Prostate‐specific antigen screening among young men in the United States

Abstract

BACKGROUND.Disagreement exists on the use of prostate‐specific antigen (PSA) tests for cancer‐risk stratification in young men in the United States. Little is known about the use of PSA testing in these men. To understand policy implications of risk stratification, the authors sought to characterize PSA use among young men.METHODS.The authors used the 2002 Behavioral Risk Factor Surveillance System to study prostate‐cancer screening in a representative sample of men aged 40 years and older (n = 58,511). The primary outcome was self‐report of a PSA test in the previous year.RESULTS.Among men aged 40 to 49 years, 22.5% (95% confidence interval [CI], 21.5‐23.5) reported having had a PSA test in the previous year, compared with 53.7% (95% CI, 52.8‐54.7; P < .001) of men aged ≥50 years. When sociodemographic characteristics were statistically controlled, young, black, non‐Hispanic men were more likely than young, white, non‐Hispanic men to report having had a PSA test in the previous year (odds ratio [OR], 2.42; 95% CI, 1.95‐3.01; P < .001). In young men, annual household income ≥$35,000 (OR, 1.50; 95% CI, 1.26‐1.78; P < .001) and an ongoing relationship with a physician (OR, 2.52; 95% CI, 2.06‐3.07; P < .001) were associated with PSA testing.CONCLUSIONS.One‐fifth of young men reported having had a PSA test within the previous year. Young, black, non‐Hispanic men are more likely than young, white, non‐Hispanic men to report having had a PSA test, although screening in this high‐risk group remains suboptimal. Cancer 2008. © 2008 American Cancer Society.

Prostate cancer screening in Switzerland: 20-year trends and socioeconomic disparities

“…This contrasts with the very low prevalence of colorectal cancer screening -which efficacy has been clearly demonstrated -recently reported using the same source population (Fedewa et al, 2015). The rise is striking given the serious debate regarding recommendations and could be, at least in part, attributed to the rapid uptake of PSA (Finney Rutten et al, 2005;Potosky et al, 1995;Scales et al, 2008). Similar high prevalence was found among men who reported having a general practitioner visit in …”

“…Indeed, because PCa screening has not been demonstrated to be beneficial and has, in fact, been demonstrated to be harmful to some, what typically is thought of as protective factor (high SES) is better conceptualized here as a risk factor. PSA testing is more common among high SES men (Nijs et al, 2000;Scales et al, 2008) and this contributes to the evidence that men who have higher SES have higher incidence of PCa but are also more likely to have localized and/or low grade at diagnosis and lower mortality (Rundle et al, 2013). Thus, higher SES may lead to higher medical surveillance and screening, including cancer screening with unclear benefits and clear harms.…”

“…These include greater access to health care facilities, health literacy and health-oriented behavior, fewer transportation barriers, social environment, and cognitive and psychological explanations (Bryere et al, 2014;Fitzpatrick et al, 1998;Rundle et al, 2013;Tobias-Machado et al, 2013;Wardle et al, 2004;Weller et al, 1998). In fact, PSA test seems to play a major role since the relationship of SES and PCa generally observed (Nijs et al, 2000;Scales et al, 2008) was not observed before PSA test was widely available (1990s) (Liu et al, 2001). Switzerland has universal health-insurance coverage, permitting access to a broad range of services.…”

Distribution de l’antigène spécifique de la prostate dans une population sénégalaise

“…Il permet le sujets de race noire de commencer le dépistage à partir de 40 ans car la maladie peut être diagnostiquée chez des sujets jeunes, de moins de 50 ans. [9][10][11].…”

Update on Screening in Prostate Cancer Based on Recent Clinical Trials

“…In contrast, the US Preventive Services Task Force concludes that there are insufficient evidences in men under the age of 75 years to assess the balance between benefits and side effects associated with screening, and the panel also recommended against screening in men over the age of 75 years [10]. Even without consensus on routine screening, more than half of US men aged 50 and older report having had a PSA test within the past year [11]. Even in the UK, where PSA screening is less common, two-thirds of the men referred to urologist with an elevated PSA were unaware that they had even had their PSA done.…”